Oblenio Bio doses first patients in LBL-051 autoimmune Phase 1a trial
Oblenio Bio, the European joint-venture company formed by Nanjing-based Leads Biolabs and Aditum Bio, has dosed its first patients in a Phase 1a first-in-human trial of LBL-051, a tri-specific T-cell engager (TCE) designed to treat refractory autoimmune diseases. The study is running across multiple European centres and received regulatory approval from Germany's Paul Ehrlich Institute.
LBL-051 simultaneously targets BCMA, CD19 and CD3, positioning it to deplete a broader spectrum of pathogenic B cells and plasma cells than current single-target or bispecific agents. The rationale is an "immune reset": stripping out the long-lived plasma cells responsible for autoantibody production with the intention of achieving sustained, drug-free remission. Leads Biolabs says preclinical data presented at EULAR 2026 showed complete depletion of peripheral and tissue B cells and plasma cells in non-human primates, with immature, non-memory B cells re-emerging on recovery. Notably, the model showed no cytokine release syndrome even at high exposure, a meaningful safety signal given that CRS has been a limiting factor for T-cell engaging therapies in other settings.
Trial design and the immune-reset rationale
The open-label, multicentre Phase 1a study uses a subcutaneous dosing regimen and a step-up dose-escalation scheme. It is enrolling patients across multiple refractory autoimmune indications rather than a single disease, with endpoints covering safety, tolerability, clinical response, and B-cell and plasma-cell depletion in both blood and tissue. That broad enrolment strategy reflects the mechanistic bet: if LBL-051's activity is defined at the biology level rather than the indication level, early proof-of-concept across several diseases could substantially de-risk the asset before Phase 2 indication selection.
Leads Biolabs founder and CEO Xiaoqiang Kang said the Phase 1a initiation demonstrates that the company's NewCo collaboration model, which pairs Chinese-originated innovation with international clinical development infrastructure, is "progressing as planned, with milestone value steadily materialising." Leads Biolabs retains eligibility for milestone payments and royalties as the originating innovator and continues to provide technical support to Oblenio.
Market context and competitive landscape
The use of TCE biology in autoimmune disease is an area of intense activity in 2026, driven partly by early clinical signals from CD19-directed CAR-T therapies in lupus and other conditions. Several companies, including larger biopharmaceutical groups and a number of clinical-stage biotechs, are pursuing B-cell and plasma-cell depletion strategies. The appeal of an off-the-shelf TCE over personalised CAR-T, should the safety and efficacy data hold up in humans, is straightforward: lower manufacturing complexity, faster access and potentially broader patient reach.
LBL-051's tri-specific format is its primary differentiating claim. By adding BCMA targeting alongside CD19, the molecule aims to address the plasma-cell population that CD19-only approaches can miss, a gap that has been cited in the literature as a potential mechanism of incomplete or non-durable responses. Whether the non-human primate data translate to a clean CRS profile in patients will be the critical near-term question, alongside depth and durability of depletion across the enrolled autoimmune indications.
Leads Biolabs notes that LBL-051 follows LBL-034, an earlier TCE asset that has received clinical validation in haematological malignancies, lending some platform credibility. Investors and potential partners will be watching for interim safety data from the ongoing Phase 1a, with any signal on drug-free remission likely to be a catalyst for partnership interest or further financing at the Oblenio level.